• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RZLT

    Rezolute Inc.

    Subscribe to $RZLT
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

    IPO Year:

    Exchange: NASDAQ

    Website: rezolutebio.com

    Peers

    $AEMD
    $XOMA
    $OGEN

    Recent Analyst Ratings for Rezolute Inc.

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    11/15/2021$30.00 → $18.00Market Outperform
    JMP Securities
    9/8/2021$21.00Buy
    ROTH Capital
    See more ratings

    Rezolute Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Rezolute with a new price target

      Craig Hallum initiated coverage of Rezolute with a rating of Buy and set a new price target of $14.00

      6/4/24 8:07:09 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Rezolute with a new price target

      Maxim Group initiated coverage of Rezolute with a rating of Buy and set a new price target of $8.00

      4/9/24 8:05:18 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Rezolute with a new price target

      Canaccord Genuity resumed coverage of Rezolute with a rating of Buy and set a new price target of $17.00

      8/2/22 7:22:19 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Rezolute with a new price target

      Cantor Fitzgerald initiated coverage of Rezolute with a rating of Overweight and set a new price target of $9.00

      6/15/22 7:36:30 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Rezolute with a new price target

      Canaccord Genuity reiterated coverage of Rezolute with a rating of Buy and set a new price target of $17.00 from $30.00 previously

      11/29/21 8:15:56 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Rezolute with a new price target

      JMP Securities reiterated coverage of Rezolute with a rating of Market Outperform and set a new price target of $18.00 from $30.00 previously

      11/15/21 8:14:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Rezolute with a new price target

      ROTH Capital initiated coverage of Rezolute with a rating of Buy and set a new price target of $21.00

      9/8/21 11:02:29 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care